What Medac does

Medac GmbH is a privately-owned German specialty pharmaceutical company founded in 1970 and headquartered in Wedel, near Hamburg. The company focuses on four therapeutic areas — rheumatology, urology, hematology, and oncology — developing, manufacturing, and distributing proprietary pharmaceutical products and diagnostics. Its core capabilities include sterile pharmaceutical manufacturing at three sites in Germany (Wedel, Dessau-Roßlau) and the Czech Republic (Brno), a portfolio of established and innovative products (notably GRAFAPEX/treosulfan for stem cell transplantation and the Hexvix blue light cystoscopy diagnostic for bladder cancer), and decades of expertise in addressing unmet therapeutic needs.

The company's business model combines direct pharmaceutical product sales with a licensing and partnership channel for geographic expansion. Products are sold and distributed through a wholly-owned subsidiary network covering at least 15 countries across Europe, Asia, and the Middle East, reaching healthcare providers in over 90 countries. Selected products (e.g., GRAFAPEX in the US) are commercialized via licensing partners such as Medexus Pharmaceuticals, which launched the product in February 2025 and projects it to exceed $100M in annual product-level net revenue within five years. The company also operates a CDMO service offering leveraging its manufacturing infrastructure, and engages in medical-scientific collaborations such as the 2026 EAU symposium with Photocure ASA. With 2,000+ employees globally, Medac serves a diversified base of healthcare providers (hospitals, transplant centers, oncology clinics, and specialist practices) with regulated, quote-based pricing through national healthcare systems and distribution channels.

Name

Medac

Legal name

medac GmbH

Website

https://international.medac.de

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Medac is a privately-owned German specialty pharmaceutical company founded in 1970, developing and manufacturing proprietary drugs and diagnostics across rheumatology, urology, hematology, and oncology for distribution in 90+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Oncology therapeutics
• Hematology treatments
• Urology therapies
• Rheumatology medications

Headquarters

HQ city

Wedel

HQ country

Germany

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Direct sales of proprietary pharmaceutical products and diagnostics across four key therapeutic areas: rheumatology, urology, hematology, and oncology. Products manufactured in Germany and Europe and distributed globally.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Medac develops, manufactures, and distributes proprietary pharmaceutical products and diagnostics across four key therapeutic areas: rheumatology, urology, hematology, and oncology. All products are manufactured in Germany and Europe to the highest pharmaceutical standards, including sterile manufacturing for oncology and hematology treatments, and are distributed across more than 90 countries worldwide. The company also licenses products to regional commercialization partners in selected territories.

Product overview

medac is a privately-owned pharmaceutical company founded in Germany in 1970, specializing in improving established pharmaceutical products and diagnostics as well as developing new therapies. The company operates across four key therapeutic areas: Rheumatology (key treatments for chronic rheumatic diseases), Urology (proprietary products addressing unmet therapeutic needs), Hematology (innovative products for stem cell transplantation therapies), and Oncology (reliable supply of medicinal products and supportive therapeutics). All products are manufactured in Germany and Europe to the highest standards and distributed across over 90 countries worldwide. The company also collaborates on diagnostic technologies like Hexvix blue light cystoscopy for bladder cancer diagnosis.

Differentiator

Problem solved

Functional benefit

Products and services

• Rheumatology Treatments Key rheumatological treatment improved by medac, targeting chronic treatment needs across a broad spectrum of patients with rheumatic diseases, bringing significant improvement to patients' quality of life.
• Urology Products A range of proprietary urological products developed to address unmet therapeutic needs. Urology has been a focus area of highest importance for medac, with the company active in this field from almost the very beginning of its corporate history.
• Hematology Products Innovative products for therapies before and after stem cell transplantation, addressing critical needs in hematology and finding new treatment approaches for rare diseases. Includes GRAFAPEX (treosulfan) for stem cell transplantation, which is licensed to Medexus Pharmaceuticals for the US market.
• Oncology Products Medicinal products and supportive therapeutics across a range of oncological indications, including sterile pharmaceutical production, representing a key focus and cornerstone of medac's decades-long track record of reliable supply in cancer care.
• Hexvix Blue Light Cystoscopy Bladder cancer diagnostic product used in blue light cystoscopy procedures, part of medac's collaboration with Photocure for optimizing bladder cancer care pathways, presented at the 2026 European Association of Urology congress.

Quantifiable outcome

• GRAFAPEX achieved 30% sequential quarter-over-quarter growth in underlying patient demand
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Photocure ASAminorStrategic or Co-development Partner · 1 March 2026Medac participated in a scientific symposium with Photocure at the 2026 European Association of Urology congress focused on optimizing bladder cancer care pathways. Both companies operate in urology space with complementary products for bladder cancer diagnosis and treatment.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Stada Arzneimittel: German-headquartered specialty pharmaceutical company of comparable scale with a diversified portfolio across multiple therapeutic areas and global distribution. Comparable to medac in being a privately-aligned, vertically-integrated German pharma with manufacturing in Europe and broad geographic reach.
• Merz Pharma: Privately-owned German specialty pharmaceutical company with focus on aesthetics, neurology, and specialty therapeutics. Comparable to medac as a privately-held German pharma with diversified specialty portfolio and long operating history.

Broad incumbents

• Ipsen: European specialty pharmaceutical company with strong oncology and urology franchises. Comparable to medac in its specialty focus on oncology and urology, though Ipsen operates as a larger publicly-listed entity with a broader commercial footprint.
• Recordati: Italian specialty pharmaceutical company with operations across multiple therapeutic areas including urology and rare diseases. Comparable to medac in its European specialty pharma positioning and presence in urology and rare disease segments.
• Almirall: Spanish specialty pharmaceutical company with European focus on dermatology and specialty therapeutics. Comparable to medac as a European-headquartered specialty pharma operating across multiple therapeutic areas with manufacturing and distribution in core European markets.
• Astellas Pharma: Japanese pharmaceutical company with significant urology and oncology franchises including stem cell transplantation products. Comparable to medac in its overlapping urology and hematology focus, though Astellas operates at substantially greater scale.
• UCB: Belgian specialty pharmaceutical company with strong presence in immunology and rheumatology. Comparable to medac in its specialty pharma positioning and overlapping rheumatology therapeutic focus.
• Bristol-Myers Squibb: Global pharmaceutical leader with deep oncology and hematology franchises. Comparable to medac in its overlapping oncology and hematology focus, though BMS operates as a substantially larger innovator with first-in-class capabilities.

Emerging players

• Photocure ASA: Norwegian specialty pharmaceutical company focused on bladder cancer diagnosis with Hexvix/Cysview blue light cystoscopy. Direct strategic collaboration partner of medac in bladder cancer care and a peer in the urology oncology space.
• Medexus Pharmaceuticals: North American specialty pharmaceutical company licensing GRAFAPEX from medac for US commercialization. Directly comparable as a specialty pharma partner with overlapping therapeutic area focus in hematology and transplantation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medac